IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
StockNews.AI · 413 days
High Materiality10/10
AI Summary
IRMD estimates Q4 2024 revenue at $19.2M to $19.4M, 10%-11% year-over-year growth. Full-year 2024 revenue expected between $73.1M to $73.3M, 11%-12% increase from 2023. Iradimed has achieved 14 consecutive quarters of record revenue growth. Strong Q4 orders indicate a robust backlog for future growth. Iradimed presents at J.P. Morgan Conference, enhancing investor visibility.
Sentiment Rationale
Consistent revenue growth and successful product offerings indicate strong market position. Previous examples of similar trends have led to stock price increases.
Trading Thesis
The ongoing demand and recorded growth suggest sustained performance over the longer term, similar to past financial cycles.
Market-Moving
- IRMD estimates Q4 2024 revenue at $19.2M to $19.4M, 10%-11% year-over-year growth.
- Full-year 2024 revenue expected between $73.1M to $73.3M, 11%-12% increase from 2023.
- Iradimed has achieved 14 consecutive quarters of record revenue growth.
Key Facts
- IRMD estimates Q4 2024 revenue at $19.2M to $19.4M, 10%-11% year-over-year growth.
- Full-year 2024 revenue expected between $73.1M to $73.3M, 11%-12% increase from 2023.
- Iradimed has achieved 14 consecutive quarters of record revenue growth.
- Strong Q4 orders indicate a robust backlog for future growth.
- Iradimed presents at J.P. Morgan Conference, enhancing investor visibility.
Companies Mentioned
- IRMD (IRMD)
Corporate Developments
The article provides critical revenue forecasts directly impacting investor sentiment and stock valuation.